Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Stanford University
- Registration Number
- NCT02451462
Pre-operative Zoledronate in Triple Negative Breast Cancer
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-11-06
- Target Recruit Count
- 22
- Registration Number
- NCT02347163
- Locations
- 🇮🇹
Oncologia 2 Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 60
- Registration Number
- NCT02325414
- Locations
- 🇺🇸
Rehabilitation Institute of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Prolonged Protection From Bone Disease in Multiple Myeloma
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Thomas Lund
- Target Recruit Count
- 158
- Registration Number
- NCT02286830
- Locations
- 🇩🇰
Odense University Hospital, Odense C, Denmark
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
- Conditions
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT02176382
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Zoledronic Acid in Rheumatoid Arthritis
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Carmen Gómez-Vaquero
- Target Recruit Count
- 28
- Registration Number
- NCT02123264
- Locations
- 🇪🇸
Hospital de Viladecans, Viladecans, Barcelona, Spain
🇪🇸Hospital Residència Sant Camil, Sant Pere de Ribes, Barcelona, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT02069340
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸J.Craig Venter Institute-San Diego, San Diego, California, United States
Zoledronic Acid Administration in Acute Spinal Cord Injury
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT02042872
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 226
- Registration Number
- NCT01951586
- Locations
- 🇬🇧
Research Site, Preston, United Kingdom
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 487
- Registration Number
- NCT01920568
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.